Experimental HIV vaccine passes first safety check in small trial
NCT ID NCT03934541
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 25 times
Summary
This early-stage study tested a new HIV vaccine in 24 healthy, HIV-negative adults to see if it is safe and can trigger an immune response. The vaccine uses a liposome (a tiny fat bubble) to deliver a piece of the HIV virus. The main goal was to check for side effects and measure antibody production. This is a first step toward developing a vaccine to prevent HIV infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS
Birmingham, Alabama, 35294, United States
-
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
Boston, Massachusetts, 02115-6110, United States
-
Columbia P&S CRS
New York, New York, 10032-3732, United States
-
Fenway Health (FH) CRS
Boston, Massachusetts, 02215-4302, United States
-
New York Blood Center CRS
New York, New York, 10065, United States
-
Seattle Vaccine and Prevention CRS
Seattle, Washington, 98109-1024, United States
Conditions
Explore the condition pages connected to this study.